Published in Biotech Business Week, March 31st, 2003
Specifically, in July 2002, the FDA approved a new drug application (NDA) for a single ingredient guaifenesin 600 mg extended release drug product Mucinex, produced by Adams Laboratories. Following this approval, the FDA reviewed the marketing status of all strengths of single ingredient extended release guaifenesin products and determined that all such unapproved products should no longer be marketed in light of the existence of an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.